Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Average Rating of “Moderate Buy” by Brokerages

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has received an average rating of “Moderate Buy” from the twenty-six ratings firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and twenty-one have given a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $319.17.

Several research analysts have commented on the stock. Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, May 8th. Canaccord Genuity Group increased their price target on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a “buy” rating in a research note on Friday, March 21st. Royal Bank of Canada increased their price target on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an “outperform” rating in a research note on Friday, March 21st. JPMorgan Chase & Co. upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $280.00 to $328.00 in a research note on Monday, March 24th. Finally, UBS Group raised their target price on shares of Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the stock a “buy” rating in a research note on Friday, May 2nd.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY opened at $302.46 on Wednesday. Alnylam Pharmaceuticals has a fifty-two week low of $152.30 and a fifty-two week high of $310.22. The firm’s 50 day moving average price is $265.72 and its 200 day moving average price is $257.99. The company has a market cap of $39.44 billion, a P/E ratio of -139.38 and a beta of 0.22. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million for the quarter, compared to analysts’ expectations of $584.32 million. During the same quarter in the prior year, the firm posted ($0.16) earnings per share. The firm’s revenue for the quarter was up 20.2% compared to the same quarter last year. On average, research analysts forecast that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 31,640 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, May 30th. The shares were sold at an average price of $304.39, for a total transaction of $9,630,899.60. Following the completion of the transaction, the chief executive officer now owns 48,948 shares in the company, valued at approximately $14,899,281.72. The trade was a 39.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 1.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Regeneron Pharmaceuticals Inc. purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $1,045,822,000. Norges Bank purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $577,941,000. Capital Research Global Investors grew its holdings in shares of Alnylam Pharmaceuticals by 32.9% during the fourth quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company’s stock worth $1,639,767,000 after buying an additional 1,724,610 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 39.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company’s stock worth $1,031,705,000 after buying an additional 1,245,195 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 2.5% during the first quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company’s stock worth $3,525,544,000 after buying an additional 323,206 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.